Top

Published in:

01-04-2009 | Review Article

Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis

Authors: Victor H. Jimenez-Zepeda, Virginia J. Dominguez-Martinez

Published in: International Journal of Hematology | Issue 3/2009

Abstract

Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma and is characterized by the presence of >20% and/or an absolute number of greater 2 × 10(9)/L plasma cells circulating in the peripheral blood. PCL represents approximately 2–4% of all MM diagnosis and exists in two forms: primary PCL (PPCL, 60% of cases) presents de novo, whereas secondary PCL (SPCL, accounts for the remaining 40%) consists of a leukemic transformation in patients with a previously diagnosed MM. Because the mechanisms contributing to the pathogenesis of PCL are not fully understood, immunophenotyping, genetic evaluation (conventional karyotype, FISH, GEP and array-CGH), and immunohistochemistry are really important tools to investigate why plasma cells escape from bone marrow and become highly aggressive. Since treatment with standard agents and steroids is poorly effective, a combination of new drugs as part of the induction regimens and bone marrow transplant (autologous and allogeneic approaches) could nearly overcome the poor prognosis exhibited by PCL patients.

Dimopoulos MA, Palumbo A, Delasalle KB, et al. Primary plasma cell leukaemia. Br J Haematol. 1994;88:754–9. doi:10.1111/j.1365-2141.1994.tb05114.x.CrossRefPubMed

International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57. doi:10.1046/j.1365-2141.2003.04355.x.

Cai ZJ. Primary plasma cell leukemia—a comprehensive analysis of 44 cases. Zhonghua Zhong Liu Za Zhi. 1990;12:314–7.PubMed

Woodruff RK, Malpas JS, Paxton AM, et al. Plasma cell leukemia (PCL): a report on 15 patients. Blood. 1978;52:839–45.PubMed

Kosmo MA, Gale RP. Plasma cell leukemia. Semin Hematol. 1987;24:202–8.PubMed

Hasmoni MH, Wahid FA, Keng CS. Primary plasma cell leukemia presented as progressive paraplegia: a case report. South Med J. 2009;102(1):101–3.CrossRefPubMed

Costello R, Sainty D, Bouabdallah R, et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res. 2001;25:103–7. doi:10.1016/S0145-2126(00)00102-8.CrossRefPubMed

Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blade J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032–7.PubMed

Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Int Med. 1974;133:813. doi:10.1001/archinte.133.5.813.CrossRef

10.

Baim BJ. Blood cells: a practical guide. Oxford: Blackwell Science; 1995.

11.

Colović M, Janković G, Suvajdzić N, Milić N, Dordević V, Janković S. Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol. 2008;25(2):154–60. doi:10.1007/s12032-007-9011-5.CrossRefPubMed

12.

Wohrer S, Ackermann J, Baldia C, et al. Effective treatment of primary plasma cell leukaemia with thalidomide and dexamethasone—a case report. Hematol J. 2004;5(4):361–3. doi:10.1038/sj.thj.6200375.CrossRefPubMed

13.

Jain D, Singh T, Akhila L, Ghosh N. Primary plasma cell leukemia in a 30-year-old woman. Indian J Pathol Microbiol. 2008;51(3):456–7.CrossRefPubMed

14.

Urashima M, Teoh G, Ogata A, et al. Characterization of p16 (INK4A) expression in multiple myeloma and plasma cell leukaemia. Clin Cancer Res. 1997;3:2173–9.PubMed

15.

Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma and plasma cell leukaemia. Hematol Oncol Clin North Am. 1999;13:1229–79. doi:10.1016/S0889-8588(05)70125-8.CrossRef

16.

Bjorkholm M, Osby E. Fludarabine and plasma cell leukemia. Eur J Haematol. 1995;54:334–5.CrossRefPubMed

17.

San Miguel JF, García-Sanz R, González M, et al. Immunophenotype heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Br J Haematol. 1991;77:185. doi:10.1111/j.1365-2141.1991.tb07975.x.CrossRefPubMed

18.

San Miguel JF, González M, Gascón A, Moro MJ, Hernández JM, Ortega F, et al. Lymphoid subsets and prognostic factors in multiple myeloma. Br J Haematol. 1991;80:305. doi:10.1111/j.1365-2141.1992.tb08137.x.CrossRef

19.

González M, San Miguel JF, Gascón A, Moro MJ, Hernández JM, Ortega F, et al. Increased expression of natural killer-associated and activated antigens in multiple myeloma. Am J Hematol. 1992;39:84. doi:10.1002/ajh.2830390203.CrossRefPubMed

20.

García-Sanz R, Orfão A, González M, Moro MJ, Hernández JM, Bŕez A, et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol. 1996;93:81. doi:10.1046/j.1365-2141.1996.4651006.x.CrossRefPubMed

21.

Orfão A, García-Sanz R, López-Berges MC, Vidriales MB, González M, Caballero MD, et al. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry. 1994;17:332. doi:10.1002/cyto.990170409.CrossRefPubMed

22.

Ocqueteau M, Orfão A, Almeida J, Bladé J, González M, García-Sanz R, et al. Immunophenotype of plasma cells from “monoclonal gammopathy of undetermined significance” (MGUS) patients. Am J Pathol. 1998;152:1655.PubMedPubMedCentral

23.

Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–75. doi:10.1182/blood-2002-10-3017.CrossRefPubMed

24.

Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terre C, Lafage-Pochitaloff M, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001;97:822–5. doi:10.1182/blood.V97.3.822.CrossRefPubMed

25.

Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22:1044–52. doi:10.1038/leu.2008.4.CrossRefPubMedPubMedCentral

26.

Chang H, Sloan S, Li D, Patterson B. Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet. 2005;156:150–3. doi:10.1016/j.cancergencyto.2004.05.004.CrossRefPubMed

27.

Jehn U. Diagnostik und therapie der plasmazell-leukamie. Tumordiagn Ther. 2002;23:135–6. doi:10.1055/s-2002-33857.CrossRef

28.

Taniwaki M, Nishida K, Ueda et al. Non random chromosomal rearrangements and their implications in clinical features and outcome in multiple myeloma and plasma cell leukaemia. Leuk Lymphoma. 1996;21:25–30. doi:10.3109/10428199609067575.

29.

Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma and plasma cell leukaemia. Hematol Oncol Clin North Am. 1999;13:1229–79. doi:10.1016/S0889-8588(05)70125-8.CrossRef

30.

Lloveras E. Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukaemia. Cancer Genet Cytogenet. 2004;148(1):71–6. doi:10.1016/S0165-4608(03)00233-4.CrossRefPubMed

31.

Schultheis B, Kramer A, Willer A, Hegenbart U, Goldschmidt H, Hehlmann R. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia. 1999;13:2099–103. doi:10.1038/sj/leu/2401609.CrossRefPubMed

32.

Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106:2837–40. doi:10.1182/blood-2005-04-1411.CrossRefPubMedPubMedCentral

33.

Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, et al. Clinical significance of TP53 mutation in myeloma. Leukemia. 2007;21:582–4. doi:10.1038/sj.leu.2404524.CrossRefPubMed

34.

Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001–14. doi:10.1093/emboj/17.17.5001.CrossRefPubMedPubMedCentral

35.

Eymin B, Gazzeri S, Brambilla C, Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene. 2002;21:2750–61. doi:10.1038/sj.onc.1205359.CrossRefPubMed

36.

Esteller M, Cordon-Cardo C, Corn PG, Meltzer SJ, Pohar KS, Watkins DN, et al. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res. 2001;61:2816–21.PubMed

37.

Magdinier F, Wolffe AP. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA. 2001;98:4990–5. doi:10.1073/pnas.101617298.CrossRefPubMedPubMedCentral

38.

Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108:1724–32. doi:10.1182/blood-2006-03-009910.CrossRefPubMedPubMedCentral

39.

Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20:2034–40. doi:10.1038/sj.leu.2404403.CrossRefPubMed

40.

Chang H, Qi X, Trieu Y, Xu W, Reader JC, Ning Y, et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol. 2006;135:486–91. doi:10.1111/j.1365-2141.2006.06325.x.CrossRefPubMed

41.

Chang H, Ning Y, Qi X, Yeung J, Xu W. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol. 2007;139:51–4. doi:10.1111/j.1365-2141.2007.06750.x.CrossRefPubMed

42.

Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–84. doi:10.1182/blood-2006-07-038430.CrossRefPubMed

43.

Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489–95. doi:10.1182/blood-2006-08-040410.CrossRefPubMed

44.

Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546–58. doi:10.1158/0008-5472.CAN-03-2876.CrossRefPubMed

45.

Chang H, Qi XY, Samiee S, Yi QL, Chen C, Trudel S, et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant. 2005;36:793–6. doi:10.1038/sj.bmt.1705131.CrossRefPubMed

46.

Chang H, Qi X, Yeung J, Reece D, Xu W, Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res. 2009;33(2):259–62. doi:10.1016/j.leukres.2008.06.027.CrossRefPubMed

47.

Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood. 1990;75:1684–90.PubMed

48.

Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat. 2001;18:212–24. doi:10.1002/humu.1177.CrossRefPubMed

49.

Ortega MM, Faria RM, Shitara ES, Assis AM, Albuquerque DM, Oliveira JS, et al. N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma. Leuk Lymphoma. 2006;47:285–9. doi:10.1080/10428190500300969.CrossRefPubMed

50.

Liang DC, Shih LY, Fu JF, Li HY, Wang HI, Hung IJ, et al. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer. 2006;106:950–6. doi:10.1002/cncr.21687.CrossRefPubMed

51.

Hayman SR, Fonseca R. Plasma cell leukemia. Curr Treat Options Oncol. 2001;2(3):205–16.CrossRefPubMed

52.

Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168–71. doi:10.1182/blood-2002-01-0335.CrossRefPubMed

53.

Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004;101:558–66. doi:10.1002/cncr.20405.CrossRefPubMed

54.

Jiménez VH, Domínguez VJ, Reynoso E. Thalidomide plus dexamethasone for untreated newly diagnosed multiple myeloma patients and deep vein thrombosis. Blood. 2006;108:5093. ASH Annual Meeting Abstracts.

55.

Zangari M, Saghafifar F, Anaissie E, et al. Acquired activated protein C resistance in the absence of Factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187–92. doi:10.1097/00001721-200204000-00003.CrossRefPubMed

56.

Jiménez-Zepeda VH, Domínguez-Martínez VJ. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J. 2006;4:11. doi:10.1186/1477-9560-4-11.CrossRefPubMed

57.

Kosmo MA, Gale RP. Plasma cell leukemia with IgA paraproteinemia and hyperviscosity. Am J Hematol. 1988;28(2):113–5. doi:10.1002/ajh.2830280210.CrossRefPubMed

58.

Raj RS, Najeeb S, Aruna R, et al. Primary plasma cell leukaemia occurring in the young. Indian J Cancer. 2003;40(3):116–7.PubMed

59.

Johnson MR, Del Carpio-Jayo D, Lin P, Giralt S, Anderlini P, Champlin RE, et al. Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol. 2006;10(5):263–8. doi:10.1016/j.anndiagpath.2005.12.011.CrossRefPubMed

60.

Woodruff RK, Malpas JS, Paxton AM, Lister TA. Plasma cell leukemia (PCL): a report on 15 patients. Blood. 1978;52(4):839–45.PubMed

61.

Jiménez-Zepeda VH, Domínguez VJ. Plasma cell leukemia: a rare condition. Ann Hematol. 2006;85(4):263–7. doi:10.1007/s00277-005-0054-4.CrossRefPubMed

62.

Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia. 2005;19:449–55. doi:10.1038/sj.leu.2403647.CrossRefPubMed

63.

Ataergin S, Arpaci F, Kaya A, Cetin T, Gunhan O. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol. 2006;81(12):987–8. doi:10.1002/ajh.20672.CrossRefPubMed

64.

Jagannath S. Current standards for first-line therapy of multiple myeloma. Clin Lymphoma Myeloma. 2007;7(Suppl 5):S207–14. doi:10.3816/CLM.2007.s.024.CrossRefPubMed

65.

Jimenez-Zepeda VH, Domínguez-Martínez VJ. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? Eur J Haematol. 2006;77(3):239–44. doi:10.1111/j.1600-0609.2006.00701.x.CrossRefPubMed

66.

Dimopoulos MA, Kastritis E. Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy? Leuk Lymphoma. 2006;47(11):2271–2. doi:10.1080/10428190600908620.CrossRefPubMed

67.

Musto P, Greco MM, Falcone A, Carotenuto M. Treatment of plasma cell leukaemia and resistant/relapsed multiple myeloma with vincristine, mitoxantrone and dexamethasone (VMD protocol). Br J Haematol. 1991;79:655–6. doi:10.1111/j.1365-2141.1991.tb08101.x.CrossRefPubMed

68.

Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, Padilla-González Y, García-Chávez J, Tripp-Villanueva F, et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol. 2002;81(7):362–7. doi:10.1007/s00277-002-0480-5.CrossRefPubMed

69.

Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia. 2008;22(12):2292. doi:10.1038/leu.2008.288.CrossRef

70.

Morris TC, Kettle PJ, Drake M, Jones FC, Hull DR, Boyd K, et al. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. Br J Haematol. 2008;143(3):349–54. doi:10.1111/j.1365-2141.2008.07360.x.CrossRefPubMed

71.

Pönisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol. 2008;143(2):191–200. doi:10.1111/j.1365-2141.2008.07076.x.CrossRefPubMed

72.

Cibeira MT, Rosiñol L, Ramiro L, Esteve J, Torrebadell M, Bladé J. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol. 2006;77(6):486–92. doi:10.1111/j.0902-4441.2006.t01-1-EJH2783.x.CrossRefPubMed

73.

Johnston RE, Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma. 2002;43(2):351–4. doi:10.1080/10428190290006143.CrossRefPubMed

74.

Brück P, Mousset S, Bühme A, Hoelzer D, Atta J. Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment. Int J Hematol. 2007;86(1):66–8. doi:10.1532/IJH97.E0617.CrossRefPubMed

75.

Wöhrer S, Ackermann J, Baldia C, Seidl S, Raderer M, Simonitsch I, et al. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone—a case report. Hematol J. 2004;5(4):361–3. doi:10.1038/sj.thj.6200375.CrossRefPubMed

76.

Petrucci MT, Martini V, Levi A, Gallucci C, Palumbo G, Del Bianco P, et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma. 2007;48(1):180–2. doi:10.1080/10428190601007570.CrossRefPubMed

77.

Bauduer F. Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma. Br J Haematol. 2002;117(4):996–7. doi:10.1046/j.1365-2141.2002.03537_4.x.CrossRefPubMed

78.

Anderson KC. Lenalidomide and thalidomide: mechanisms of action–similarities and differences. Semin Hematol. 2005;42:S3–8. doi:10.1053/j.seminhematol.2005.10.001.CrossRefPubMed

79.

Dimopoulos MA, Kastritis E, Rajkumar SV. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia. 2008;22(7):1343–53. doi:10.1038/leu.2008.123.CrossRefPubMed

80.

Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–7. doi:10.1182/blood-2002-03-0996.CrossRefPubMed

81.

List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–65. doi:10.1056/NEJMoa061292.CrossRefPubMed

82.

Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32. doi:10.1056/NEJMoa070594.CrossRefPubMed

83.

Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–42. doi:10.1056/NEJMoa070596.CrossRefPubMed

84.

Benson DM Jr, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma. 2007;48(7):1423–5. doi:10.1080/10428190701361851.CrossRefPubMed

85.

Breitkreutz I, Anderson KC. Thalidomide in multiple myeloma–clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2008;4(7):973–85. doi:10.1517/17425255.4.7.973.CrossRefPubMed

86.

Richardson P, Schlossman RI, Weller E, Hideshima T, Mitsiades C, Davies F. Immunomodulatory derivative of thalidomide CC5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–7. doi:10.1182/blood-2002-03-0996.CrossRefPubMed

87.

Muller G, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT. Amino-substituted thalidomide analogs: potent inhibitors of TNF-production. Bioorg Med Chem Lett. 1999;9:1625–30. doi:10.1016/S0960-894X(99)00250-4.CrossRefPubMed

88.

Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–30. doi:10.1182/blood.V99.12.4525.CrossRefPubMed

89.

Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008;26:480–92. doi:10.1200/JCO.2007.11.6863.CrossRefPubMed

90.

Kim SJ, Kim J, Cho Y, Seo BK, Kim BS. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol. 2007;37:382–4. doi:10.1093/jjco/hym037.CrossRefPubMed

91.

Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res. 2008;32:1153–6. doi:10.1016/j.leukres.2007.11.010.CrossRefPubMed

92.

Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D’Arena G, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007;109:2285–90. doi:10.1002/cncr.22700.CrossRefPubMed

93.

Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, Feugeas JP, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med. 2007;4:90. doi:10.1371/journal.pmed.0040090.CrossRef

94.

Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755–62. doi:10.1111/j.1365-2141.2005.05519.x.CrossRefPubMed

95.

Al-Nawakil C, Tamburini J, Bardet V, Chapuis N, Bourry E, Roux C, et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma. 2008;49(10):2012–4. doi:10.1080/10428190802290660.CrossRefPubMed

96.

Reeder CB, Reece DE, Fonseca R, Bergsagel PL, Hentz J, et al. A phase II trial of myeloma induction therapy with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D): improved response over historical lenalidomide-dexamethasone controls. Blood. 2007;110:3601. doi:10.1182/blood-2007-04-086827. ASH Annual Meeting Abstracts.CrossRef

97.

Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol. 2005;78(4):288–94. doi:10.1002/ajh.20272.CrossRefPubMed

98.

Nonami A, Miyamoto T, Kuroiwa M, Kunisaki Y, Kamezaki K, Takenaka K, et al. Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling. Jpn J Clin Oncol. 2007;37(12):969–72. doi:10.1093/jjco/hym130.CrossRefPubMed

99.

Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C, et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34:77–84. doi:10.1038/sj.bmt.1704531.CrossRefPubMed

100.

Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81(8):1047–53. doi:10.4065/81.8.1047.CrossRefPubMed

101.

Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20(17):3719–36.CrossRefPubMed

102.

Shipman CM, et al. Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma. 1998;32:129–38.CrossRefPubMed

Title: Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis
Authors: Victor H. Jimenez-Zepeda
Virginia J. Dominguez-Martinez
Publication date: 01-04-2009
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 3/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-009-0288-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab

Hemophagocytic syndrome after hematopoietic stem cell transplantation: a prospective observational study

Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease

Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura

A case of tuberculosis-induced hemophagocytic lymphohistiocytosis in a patient under hemodialysis

High diagnostic value of morphologic examination and molecular analysis of bone marrow biopsies in a case of BCR-ABL+ CML with clusters of blasts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer